Economic evaluation of anlotinib plus penpulimab vs. sorafenib as first-line therapy for unresectable hepatocellular carcinoma in China
Anlotinib plus penpulimab represents a potentially cost-effective first-line treatment for advanced HCC from a Chinese healthcare system perspective. These findings support incorporating this regimen into guidelines for selecting cost-effective immunotherapeutic strategies and provide evidence to inform decision-making about resource allocation for advanced HCC management.
Authors
- Rui Fang (ORCID: https://orcid.org/0000-0001-7724-2348)
- Tieqiao Wang (ORCID: https://orcid.org/0000-0001-5354-8342)
- Jun Xu (ORCID: https://orcid.org/0000-0003-4221-5563)
- Jiajun Liang (ORCID: https://orcid.org/0000-0002-1100-4731)
- Feifeng Sheng
Institutions
- Jinan University (CN)
- Guangdong Province Women and Children Hospital (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-12-01
- DOI
- https://doi.org/10.3389/fpubh.2025.1634266
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00